SEATTLE, WA--(Marketwire - June 04, 2012) -
Atossa Genetics, Inc., a privately-held health care company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous breast lesions, today announced that Steven C. Quay, M.D., Ph.D., FCAP, Chairman, President & CEO of Atossa Genetics
and Director of the National Reference Laboratory for Breast Health
, will conduct a workshop at Active Communications International's 5th National Breast Centers of Excellence conference
, June 6-8, 2012, in Dallas, Texas.
The workshop, titled "Using Unique Molecular Tests to Grow Your Breast Center of Excellence Patient Base," will take place on Friday, June 8, from 2:15-3:15 pm Central Time. Workshop attendees will learn how to:
- Establish a Care Path for your high risk and breast cancer survivors that provides molecular information within each breast ductal-lobular system,
- Use unique FDA-cleared, patented, clinically validated tests in your breast cancer survivors to monitor "molecular" recurrence, both local and systemic, and
- Partner with a National Reference Laboratory specializing in Breast Health to differentiate your service offering.
"I am pleased to have the opportunity to conduct a workshop on molecular tests at this prestigious event," stated Steven C. Quay, M.D., Ph.D., FCAP, Chairman, President and CEO of Atossa Genetics and Director of the National Reference Laboratory for Breast Health. "Our suite of new molecular tests can provide Breast Centers of Excellence with a unique offering to help set them apart in their local markets. By partnering with a national reference laboratory for breast health, Breast Centers of Excellence can show their commitment to best practice and can set the stage for their participation with the next generation of breast cancer prevention, intraductal pharmaceutical treatment of DCIS and related pre-cancerous lesions."
About Atossa Genetics, Inc.
Atossa Genetics, Inc. is a privately held health care company based in Seattle, Washington, that provides a comprehensive set of innovative breast health evaluation products and services that provide accurate and actionable results for personalized cancer prevention and breast health. Atossa has established the National Reference Laboratory for Breast Health, a specially equipped, CLIA-certified laboratory located in Seattle that provides comprehensive test results to guide personalized breast cancer prevention and treatment solutions.
About the National Reference Laboratory for Breast Health
The National Reference Laboratory for Breast Health, a division of Atossa Genetics, Inc., is focused on developing novel, clinically relevant tests for evaluating Breast Health in all women. The National Reference Laboratory for Breast Health, located in Seattle, Washington, is the only CLIA-registered laboratory focused exclusively on breast health. The National Reference Laboratory for Breast Health provides comprehensive test results to guide personalized breast cancer prevention and treatment solutions. For additional information on the ForeCYTE Breast Health Test and the ArgusCYTE Breast Health Test, please visit www.NRLBH.com.
About the Breast Center of Excellence Designation
The Breast Imaging Center of Excellence (BICOE) designation is awarded to breast imaging centers that achieve excellence by seeking and earning accreditation in all of the American College of Radiology's voluntary breast-imaging accreditation programs and modules, in addition to the mandatory Mammography Accreditation Program.